Excelsior Biopharma Inc. 6496.TWO TWO · Healthcare · Taiwan
$23.15 -1.07% -$0.25
Summary
43 / 100 · Bulios Score
What speaks for it
- Revenue grew by 10% a year over the last 3 years.
What to watch
- The company made a loss over the last 12 months.
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedBy our assumptions the price matches the value of the business: the two differ by less than 10 %.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
SlowlyRevenue (TWD)
Diluted EPS (TWD)
Revenue fell by 9.1% a year over 5 years. Over the last 3 years it grew by 10% a year.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $184.7M.
Profitability in detailIs it financially healthy?
Debt is a burdenOver the last 12 months it spent more cash than it brought in. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detail